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Background: Alzheimer’s disease (AD) is the most common form of dementia. Mutations in genes such as those
encoding amyloid precursor protein (APP), presenilin 1 and presenilin 2, are responsible for early-onset familial AD.
Case presentation: In this study, we report a 275341 G > C (Val717Leu) mutation in the APP gene in a Japanese
family with early onset AD by genetic screening. This mutation has previously been detected in European families.
In the Japanese family we screened, the age at onset of AD was 47.1 ± 3.1 years old (n = 9; range, 42–52). The
symptoms in the affected members included psychiatric vulnerability and focal signs such as pyramidal signs,
epileptic seizures, and myoclonic discharges. An MR imaging study showed relatively mild atrophic changes in the
bilateral hippocampus and cerebral cortices in all affected members compared with their clinical presentations.
Conclusion: We conclude that the clinical features of Alzheimer’s disease can be different even when caused by
the same mutation in the APP gene. Further clinical and genetic studies are required to clarify the relationship
between phenotypes and genotypes.Background
Alzheimer’s disease (AD) is the most common type of
dementia, with a prevalence of over 26 million world-
wide [1]. According to the definition of National Insti-
tute of Neurological and Communicative Disorders and
Stroke–Alzheimer’s Disease and related Disorders Asso-
ciation [2], AD is diagnosed based on detection of two
of the following symptoms: amnesia, aphasia, apraxia
and agnosia. Atrophic changes occur in the parietal and
temporal cortices, especially the medial temporal lobe
including hippocampus. The pathological changes in AD
include amyloid plaques (include amyloid beta protein)
and neurofibrillary tangles (including hyperphosphory-
lated tau protein).
Amyloid plaques consist primarily of amyloid β protein
(Aβ), which is produced when APP is cleaved by β-
secretase and then cleaved again by γ-secretase as part of
the amyloidogenic pathway. According to the amyloid cas-
cade hypothesis, an imbalance between Aβ production
and clearance plays a role in the progression of AD. Aβ* Correspondence: masao-a@m.ehime-u.ac.jp
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reproduction in any medium, provided the oroligomers may directly inhibit hippocampal long-term po-
tentiation and impair synaptic function in addition to the
inflammatory and oxidative stress caused by aggregated
and deposited Aβ as amyloid plaques. These processes
lead to neurotransmitter deficits and the cognitive symp-
toms associated with disease progression [3,4].
The age of onset of AD is usually after the age of
65 years, but can be earlier if influenced by genetic muta-
tions in familial Alzheimer genes. In early-onset familial
AD, mutations in the genes related to the amyloid cas-
cade, amyloid precursor protein (APP), presenilin 1 (PS1),
and presenilin 2 (PS2), have been found. There are cur-
rently 32 known mutations in APP, 178 in PS1, and 14 in
PS2, and these have been identified in 86, 392, and 23
families, respectively. Mutations in these three genes ac-
count for less than 1% of all AD cases [5]. Four different
missense mutations (to an isoleucine, phenylalanine, gly-
cine, or leucine) have been reported at codon 717, encod-
ing valine, of the APP gene (for a review, see [6]). The
Val717Leu mutation in APP has been reported in
European-descendant families. In this study, we report
the first Val717Leu APP mutation to be detected in a
Japanese family, and describe the clinical signs and symp-
toms in detail.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Abe et al. BMC Neurology 2012, 12:38 Page 2 of 5
http://www.biomedcentral.com/1471-2377/12/38Case presentation
The proband developed deficits in short-term memory
and loss of concentration at the age of 45. He was a
banker with 16 years of education. When admitted to
our hospital at the age of 47, the findings of a neuro-






Figure 1 Brain MRI (FLAIR). a) III-9 at the age of 55 years, b) the prob
All siblings had generalized cerebral atrophy but this was mild relative to tstate examination (MMSE) score was 20/30. His
Raven’s colored progressive matrices (RCPM) score
was 30/36. Neuropsychological examination demon-
strated intellectual decline with impaired memory, but
preserved visuoperceptual skills. Brain MRI showed
mild generalized cerebral atrophy. His conversationL
L
L
and (III-10) at the age of 53 years, c) III-11 at the age of 52 years.
heir clinical features.
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seizures several times in a year and developed gait
disturbance at the age of 52. When he was 53 years
old (six years after first admission), myoclonus and
pyramidal signs were present. Neuropsychological test-
ing could not be carried out at this point. Figures 1a
and 2 show brain MRI and 123I-IMP SPECT findings,
respectively.
Family report
Figure 3 shows the 3-generation pedigree of a Japanese
family with early-onset Alzheimer’s disease. The age at
onset and death and unusual features are shown in
Table 1. We gathered information from medical records
of the participants including the proband (patient III-10).
The proband’s elder sister (III-9) was a nurse with
14 years of education. She left her job at the age of 40
because she had trouble performing her work as a nurse.
She showed clear short-term memory loss at the age of
45, which gradually worsened. At the age of 55, she
began losing her way home and demonstrating agitation,
aggression, irritability, lability, and urinary incontinence.
She was admitted to our hospital for further examin-
ation. She angered easily, at anything, and needed to stay
in a single room for special psychiatric care. Neurologic
examination revealed pyramidal signs bilaterally and her
MMSE score was 6/30. Brain MRI showed bilateral tem-
poral and parietal atrophy (Figure 1b). She could not live
by herself and was re-admitted to another hospital for
long-term care.
The proband’s younger sister (III-11) was a housewife
with 14 years of education. She was married and had aFigure 2 I-IMP SPECT of the proband (III-10) at the age of 53. A generchild. She presented to our hospital at the age of 52 years
with a 5-year history of gradual progressive memory diffi-
culties. Neurologic examination was normal without any
psychiatric symptoms. However, her MMSE score was
24/30 and her RCPM score was 27/36. Brain MRI
showed mild bilateral temporal and parietal atrophy
(Figure 1c).
Genetic analyses
Genomic DNA was extracted from peripheral blood leu-
cocytes from five participants (II-8, a non-affected
mother; III-7, a cousin; and III-9, 10, 11, the affected sib-
lings) according to a standard protocol, after obtaining
written informed consent approved by the Ehime Univer-
sity Ethics Committee. Written informed consent was
obtained from the patient for publication of this case re-
port and any accompanying images. A copy of the writ-
ten consent is available for review by the Editor-in-Chief
of this journal.
At first, it was planned to analyze the mutations of
known genes causing AD in the proband. Based on the
report of Finckh et al. [7], direct sequencing of the PS1
exons 1 to 12 and APP exons 16 and 17 was done be-
cause those mutations account for more than half of
family-based autosomal-dominant Alzheimer’s demen-
tia. The resulting sequences were compared with those
in normal control subjects. Sequencing analysis of the
proband (III-10) revealed no mutations in the PS1 gene.
The following primers were used for amplification and
sequencing of exon 17 of the APP gene: forward, 5′
ccaaatgtcccctgcatt 3′ and reverse, 5′ gaaacatgcagtcaagtt-
tacct 3′. The PCR master mix was composed of 12.5 μlalized decrease drop in cerebral blood flow is shown.
-1 -2
-1 -2 -3 -4 -5 -6 -7 -8 -9
-1 -2 -3 -5 -7-4 -8 -9-6 -10 -11
Figure 3 Pedigree of a Japanese family with early-onset Alzheimer disease. The arrow denotes the proband. The circles indicate females
and squares indicate males. Solid symbols denote the affected individuals; open symbols denote unaffected individuals; slashes, deceased.
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Biosystems, Austin, TX), 1.25 μl of 10× PCR Buffer,
2.5 nmol of dNTP mixture, 2.5 nmol of each primer
and 100 ng of genomic DNA. The conditions for ampli-
fication were as follows: an initial denaturing step of
94°C for 10 min, followed by 45 cycles of 94°C for 30 s,
57°C for 30 s, 72°C for 1 min, and a final elongation
step of 72°C for 9.5 min. The sequence of exon 17 of
the APP gene revealed a single nucleotide substitution
in one allele: 275341 G>C (amino acid: Val717Leu)
(Figure 4). The resulting 189-base pair product was
assessed by PCR-restriction fragment length polymor-
phism (PCR-RFLP) analysis using MnlI and run on a
4% NuSieve 3:1 agarose (Takara Bio, Japan) (Figure 5).
This mutation was not observed in 50 normal control
subjects (100 normal chromosomes).
Conclusions
By screening exon 17 of APP and the coding exons of
PS1 and PS2, a mutation detection rate of ~57% [7] can
be achieved in patients with suspected familial AD
(FAD), a figure comparable to those of earlier reports
(46–71%) [8-10]. The family described here was had aTable 1 Ages of affected members






I-2 50 65 not known
II-1 50 58 not known
II-5 42 56 not known
II-7 52 72 not known
III-1 47 54 attempt suicide
III-6 46 48 depression
III-9 45 disinhibition
III-10 45 seizure
III-11 47 poor insight
mean 47.1 ± 3.1 58.8 ± 8.5V717L mutation in exon 17 of APP. This is the first
finding of this mutation, which has been reported in sev-
eral European descendent families [3,11], in an Asian
family. In the family, age at onset of AD was
47.1 ± 3.1 years (mean ± S.D.; range, 42–52, n = 9) and
age at death was 58.8 ± 8.5 years (mean ± S.D.; range,
48–72, n = 6). These findings are different from the data
reported by Murrell et al. [3], in which age at onset was
~38 years (range, 35–39) and age at death was ~46 years
(range, 40–50), but it is similar to data reported by
Godbolt et al. [11], in which age at onset and death were
~50 (range, 48–57) and ~61 (range, 57–68), respectively.
Disease duration was the same, being ~10 years in all
three families. Because ApoE status was shown to affect
the age at onset or death and clinical features in the pre-
cedent studies, the ApoE status of the family members
was analyzed. The ApoE genotypes in III-9, III-10 and
III-11 were Ex3/Ex3, Ex3/Ex3 and Ex3/E x3, respectively
[12]. Thus, it seemed that the ApoE status was not re-
sponsible for the features in this family. In this Japanese
family, the first symptom was progressive short-term
memory impairment, as observed in typical AD. How-
ever, there were focal signs and symptoms that were
unusual for AD; for example, frontal lobe impairmentAPP ex17
V/LT V I I T
Figure 4 Sequence of exon 17 of the APP gene in affected
individuals. The part of N shows that both G and C occur at
nucleotide position 275,341 of the APP gene. This causes an amino
acid change in codon 717 (valine to leucine).
Figure 5 The results of 4% agarose gel electrophoresis of Mnl
I-digested PCR products. The mutant product is cut into two
fragments of 202 and 189 base pairs (bp) by Mnl I digestion after
PCR. Individuals III-10 (proband), III-9 and III-11 carry the mutant
allele. C represents a normal control subject.
Abe et al. BMC Neurology 2012, 12:38 Page 5 of 5
http://www.biomedcentral.com/1471-2377/12/38(depression, apathy, disinhibition) in III-6, III-9 and III-
10, pyramidal signs in III-9 and III-10, and epileptic sei-
zures and myoclonus in III-10, although there were no
focal lesions in either brain MRI or SPECT. Godbolt
et al. reported that atypical features, seizures and hallu-
cinations were apparent in several patients with the APP
Val717Leu mutation [11]. We suggest that this mutation
affects pathways other than the amyloidogenic pathway
to modify the features of AD, and that some genes and/
or environments may change the features of AD, even
with the same APP mutation.
Further clinical and genetic studies are required to
clarify the relationship between phenotypes and geno-
types and to identify additional biological factors, such
as tau, that may have a role in the pathogenesis of AD.
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